Product Pipeline

TheraCea is independently and collaboratively developing products with our radiolabeling centered on 18F because of its clinical, logistical, economic, and accessibility advantages. 18F labeling was mainly limited to small molecules; however, we are expanding our groundbreaking chemistry approach to label peptides, proteins, and antibody fragments for personalized medical applications. Our focus on 18F products allows us to distribute our pre-clinical products and clinical candidates through existing commercial infrastructure so every patient in every corner of the country will have access to reliable, safe, and effective products.